期刊文献+

非小细胞肺癌组织中FAK和pY397FAK的表达 被引量:2

Expressions of focal adhesion kinase and phosphorylated focal adhesion kinase in non-small cell lung cancer
下载PDF
导出
摘要 目的:探讨粘着斑激酶(focaladh sionkinase,FAK)和磷酸化FAK(phosph FAK,pY397FAK)在非小细胞肺癌(no smallcelllungcancer,NSCLC)和正常支气管 黏膜上皮中的表达,及FAK在NSCLC发生 浸润和转移中的作用。方法:应用免疫组织 化学方法检测FAK和pY397FAK在60例 NSCLC和19例正常支气管黏膜上皮中的表 达,并与临床病理指标和Ki 67表达进行联 合分析。结果:FAK和pY397FAK在NSCL 中表达为83.3%(50/60)和55.0%(33 60),高于正常支气管黏膜上皮[57.9%(11 19)和21.1%(4/19)],差异有统计学意义 P=0.030、P=0.010。FAK和pY397FAK表 达升高与TNM分期及淋巴结转移有关,在 Ⅲ期和淋巴结转移组的阳性率高于Ⅰ+Ⅱ 期和无淋巴结转移组,差异有统计学意义, 均<0.05。FAK的强阳性表达率在低分化 组中(73.1%,19/26)显著高于高 中分化组 (47.1%,16/34),P=0.043。结论:FAK和 pY397FAK过表达在NSCLC发生和进展中发 挥重要作用。FAK和pY397FAK可能作为判 断NSCLC生物学行为的指标和治疗的新靶 点。 OBJECTIVE: To explore the roles of FAK and its phosphorylated form, i.e.pY397FAK, in tumorigenesis, invasion and metastasis of non-small cell lung cancer (NSCLC) by detecting the expressions of FAK and pY397FAK in human normal bronchiolar epithelium and primary NSCLC.METHODS: By using the immunohistochemical method, the expressions of FAK and pY397FAK in 60 cancerous tissues and 19 normal bronchiolar epithelia were measured. The relationship between FAK, pY397FAK expressions and clinicopathological parameters as well as Ki-67 expression was analyzed.RESULTS:Elevated levels of FAK and pY397FAK expressions were detected in primary tumor (83.3%, 55.0%) compared with normal bronchiolar epithelium (57.9%, 21.1%), P=0.030,P=0.010. The expressions of FAK and pY397FAK were related with TNM stage and the lymph node involvement,P<0.05.The positive rates of FAK and pY397FAK in stage Ⅲ and lymph node metastasis groups were significantly higher than those in stage Ⅰ+Ⅱ and no lymph node metastasis groups, P<0.05. The strongly positive rate of FAK expression was 73.1% in poorly differentiated cases, 47.1% in well-moderately differentiated cases; the difference was significant between the two groups,P=0.043.CONCLUSIONS: FAK and pY397FAK are overexpressed in NSCLC and may play important roles in the pathway of carcinogenesis and progression of NSCLC. FAK and pY397FAK may be used as important indices for biologic behavior of NSCLC and identified as new therapeutic targets.
出处 《肿瘤防治杂志》 2005年第1期10-13,共4页 China Journal of Cancer Prevention and Treatment
基金 国家自然科学基金项目(39870305
关键词 肺肿瘤/病理学 粘着斑激酶 磷酸化 转移 免疫组织化学 lung neoplasms/pathology focal adhesion kinase phosphorylation metastasis immunohistochemistry
  • 相关文献

参考文献12

  • 1邵淑娟,汪洋,杨佩满.肺癌癌前病变中的分子生物学异常事件[J].癌症,2004,23(1):99-103. 被引量:7
  • 2Weiner T M, Liu E T, Craven R J, et al. Expression of focal adhesion kinase gene and invasive cancer [J]. Lancet, 1993, 342(8878): 1024-1025.
  • 3Owens L V, Xu L, Craven R J, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors [J].Cancer Res, 1995, 55(13): 2752-2755.
  • 4Rovin J D, Frierson H F, Ledinh W, et al. Expression of focal adhesion kinase in normal and pathologic human prostate tissues[J]. Prostate, 2002, 53(2): 124-132.
  • 5Lark A L, Livasy C A, Calvo B, et al. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses [J]. Clin Cancer Res, 2003 , 9(1): 215-222.
  • 6Sobin L H, Wittekind C. UICC TNM classification of malignant tumors[M]. 5ed. New York: Wiley-Liss, 1997.93-97.
  • 7Agochiya M, Brunton V G, Owens D W, et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells [J]. Oncogene, 1999, 18(41): 5646-5653.
  • 8Gabarra-Niecko V, Schaller M D, Dunty J M. FAK regulates biological processes important for the pathogenesis of cancer[J]. Cancer Metastasis Rev, 2003, 22(4): 359-374.
  • 9Schaller M D. Biochemical signals and biological responses elicited by the focal adhesion kinase [J]. Biochim Biophys Acta,2001, 1540(1): 1-21.
  • 10Richardson A, Parsons T. A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125FAK [J]. Nature, 1996, 380(6574): 538-540.

二级参考文献44

  • 1[1]Parkin DM, Pisani P, Ferlay J. Global cancer statistics [J]. C A Cancer J Clin, 1999, 49:33 - 64.
  • 2[2]Brambilla E, Gazzeri S, Lantuejoul S,et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1)in precursor bronchial lesions of lung cancer [J]. Clin Cancer Res, 1998, 4:1609 - 1618.
  • 3[3]Minna JD, Fong K, Zochbauer-Muller S, et al. Molecular pathogenesis of lung cancer and potential translational applications [J]. Cancer J, 2002, MayJun; 8 Suppl 1:S41 -46.
  • 4[4]Fong KM, Sekido Y, Minna JD.Molecular pathogenesis of lung cancer[J]. J Thorac Cardiovasc Surg, 1999,118: 1136- 1152.
  • 5[5]Chen JT, Ho WL, Cheng YW, et al.Detection of p53 mutations in sputum smears precedes diagnosis of non-small cell lung carcinoma [J]. Anticancer Res, 2000, 20:2687 - 2690.
  • 6[6]Gonzalez R, Silva JM, Sanchez A, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance [J]. Ann Oncol, 2000, 11: 1097- 1104.
  • 7[7]Chung GT, Sundaresan V, Hasleton P,et al. Clonal evolution of lung tumors[J]. Cancer Res, 1996, 56: 1609-1614.
  • 8[8]Nuorva K, Soini Y, Kamel D, et al.Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas [J]. Am J Pathol, 1993,142:725 - 732.
  • 9[9]Brambilla E, Gazzeri S, Lantuejoul S,et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1)in precursor bronchial lesions of lung cancer [J]. Clin. Cancer Res, 1998, 4:1609 - 1618.
  • 10[10]Gonzalez R, Silva JM, Sanchez A, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance [J]. Ann Oncol, 2000, 11: 1097- 1104.

共引文献6

同被引文献29

  • 1肖大凯,覃燕梅,莫丽儿,梁念慈.木犀草素对卵巢癌细胞株转移能力的影响[J].中国病理生理杂志,2006,22(6):1199-1202. 被引量:31
  • 2SCHROEDER A,HELLER D A,WINSLOW M M,et al.Treating metastatic cancer with nanotechnology[J].Nat Rev Cancer,2012,12(1):39-50.
  • 3PFISTERER P H,WOLBER G,EFFERTH T,et al.Natural products in structure-assisted design of molecular cancer therapeutics[J].Curr Pharm Des,2010,16(15):1718-1741.
  • 4LIN Y,SHI R,WANG X,et al.Luteolin,a flavonoid with potential for cancer prevention and therapy[J].Curr Cancer Drug Targets,2008,8(7):634-646.
  • 5ZHAO Y,YANG G,REN D,et al.Luteolin suppresses growth and migration of human lung cancer cells[J].Mol Biol Rep,2011,38(2):1115-1119.
  • 6GOLUBOVSKAYA V M.Focal adhesion kinase as a cancer therapy target[J].Anticancer Agents Med Chem,2010,10(10):735-741.
  • 7LI S,HUA Z C.FAK expression regulation and therapeutic potential[J].Adv Cancer Res,2008,101:45-61.
  • 8HUANG Y T,LEE L T,LEE P P,et al.Targeting of focal adhesion kinase by flavonoids and small-interfering RNAsreduces tumor cell migration ability[J].Anticancer Res,2005,25(3B):2017-2025.
  • 9ZHOU Q,YAN B,HU X,et al.Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin[J].Mol Cancer Ther,2009,8(6):1684-1691.
  • 10LEE W J,WU LF,CHEN W K,et al.Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways[J].Chem Biol Interact,2006,160(2):123-133.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部